This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

6 Jul 2012

Amgen Completes Acquisition of KAI Pharmaceuticals

Amgen has announced the completion of the acquisition of KAI Pharmaceuticals.

American-based multinational biopharmaceutical company Amgen announced Thursday the completion of the acquisition of KAI Pharmaceuticals, a privately held company based in South San Francisco.


The acquisition was initially announced April 10, 2012 and includes KAI's lead product candidate KAI-4169, which is a novel agent being studied initially for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. 


KAI has previously reported compelling Phase 2a clinical results for KAI-4169 in this indication. KAI-4169 is administered intravenously at the same time the patient is undergoing dialysis.

Related News